Aurora, sterilization from the cold

Aurora is a Normandy-based company founded in 2019 by Jan Laarman and […]

Aurora is a Normandy-based company founded in 2019 by Jan Laarman and Thomas Parias, two entrepreneurs passionateabout innovationin the healthcare sector.

Its goal is to becomea major player in the field of sterilization, supported by committed investors, shareholders, and partners.

Technology

There are currently three main processes for sterilizing heat-sensitive medical devices:

  • by ionizing radiation (gamma rays and X-rays)
  • by fumigation with ethylene oxide (at low pressure)
  • by fumigation with hydrogen peroxide (at low pressure)

Unfortunately, these sterilization methods are not always compatible with many innovative medical devices. These are often made of fragile materials such as polymers, electronics, optics, textiles, etc.

More concerning is the fact that digestive endoscopes cannot be re-sterilized. Their shapes are too complex and their materials are incompatible with steam sterilization. This results in high contamination rates: more than 20% on average in France (Pineau, 2023), exposing patients to infections.

The sterilization system developed by AURORA represents atrueinnovation:

  • By completely protecting patients exposed to potential infections from endoscopes that were previously non-sterilizable;
  • By paving the way for the arrival on the market of innovative medical devices that do not have a suitable sterilization process;
  • By offering a sterilizing agent that is non-toxic to human health and the environment, while also being energy efficient.

This technology is the result of collaboration between:

  • The CRITT-MDTS (research and expertise center specializing in materials, coatings, and surface treatments) located in Charleville-Mézières and headed by Jean-Marc Popot
  • The "Technological Developments and Industrial Interfaces" team led by Marie-Paule Gellé at the EA 4691 "BIOS" laboratory at the University of Reims Champagne-Ardenne
  • The company AURORA, led by Jan LAARMAN and Thomas PARIAS

Support from SATT Nord

SATT Nord facilitated discussions between Aurora, URCA, and CRITT MDTS and managed the negotiation of the sublicense with Aurora.

 

Key steps in Aurora Cold Plasma Sterilization

  • 2019: creation of the startup and signing of the license agreement with SATT Nord
  • 2021: First €3 million fundraising round led by GO Capital
  • 2022: Winner of the call for expressions of interest "Emerging Infectious Diseases" (AMI-MIE) as part of the France 2030 plan (non-dilutive financing of €3 million)
  • 2023: Second €2 million fundraising round with its existing shareholders.
    Winner of the EIC Accelerator (€2.5 million non-dilutive financing and commitment from the European Investment Bank).
  • 2024: submission of the technical file for CE and FDA marking and opening of an assembly plant in Normandy

What happens next?

Aurora Sterilisation is planning to obtain marketing authorization for its first natural plasma sterilizer, Aqsaniit, in Europe and the US by the end of 2025. There has been significant interest from hospital and industrial customers. These two markets are substantial (€8 billion).

  • "Thanks to SATT Nord, we were able to gain the trust of the patent owners to secure intellectual property rights and begin our efforts with venture capital funds. We are counting on the same support from SATT for the rest of our innovation strategy." Jan Laarman – CEO Aurora Sterilization